Key Points Vertex Pharmaceuticals and Amgen recently posted strong clinical trial results for promising candidates. Both companies have robust businesses and strong medium-term prospects. 10 stocks we like better than Vertex Pharmaceuticals › Vertex Pharmaceuticals (NASDAQ:VRTX) and Amgen (NASDAQ:AMGN) have both outperformed the broader market this year as of this writing. However, it might not be too late to invest in these stocks. Recent developments highlight that these drugmakers have strong pipelines and attractive medium-term prospects. Here's some recent news from Vertex Pharmaceuticals and Amgen, and why investors should seriously consider buying shares of both drugmakers. Image source: The Motley Fool. Missed AI’s "Act 1"?
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.